Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
123.31 (1y: +76%)
Market Cap 51.46 B P/E(ttm) 37.50
Enterprise Value 51.12 B P/B 9.10
CELG- NAS (USA)
Celgene Corporation
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$123.31
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 1.266
CELG's Cash to Debt is ranked lower than
77% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 1.266 )
CELG' s 10-Year Cash to Debt Range
Min: 0.51   Max: No Debt
Current: 1.27
Equity to Asset 0.047
CELG's Equity to Asset is ranked lower than
85% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. CELG: 0.047 )
CELG' s 10-Year Equity to Asset Range
Min: -0.49   Max: 0.88
Current: 0.05
-0.49
0.88
Interest Coverage 36.4
CELG's Interest Coverage is ranked lower than
59% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 36.4 )
CELG' s 10-Year Interest Coverage Range
Min: 36   Max: No Debt
Current: 36.4
F-Score: 6
Z-Score: 7.01
M-Score: -3.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry		 vs
history
Operating margin (%) 31.70
CELG's Operating margin (%) is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. CELG: 31.70 )
CELG' s 10-Year Operating margin (%) Range
Min: -91.4   Max: 31.7
Current: 31.7
-91.4
31.7
Net-margin (%) 26.4
CELG's Net-margin (%) is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. CELG: 26.4 )
CELG' s 10-Year Net-margin (%) Range
Min: -83.2   Max: 28.9
Current: 26.4
-83.2
28.9
ROE (%) 25.6
CELG's ROE (%) is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. CELG: 25.6 )
CELG' s 10-Year ROE (%) Range
Min: -43.9   Max: 25.6
Current: 25.6
-43.9
25.6
ROA (%) 12.4
CELG's ROA (%) is ranked higher than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. CELG: 12.4 )
CELG' s 10-Year ROA (%) Range
Min: -67.5   Max: 14.4
Current: 12.4
-67.5
14.4
ROC (Joel Greenblatt) (%) 210.40
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. CELG: 210.40 )
CELG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1971.5   Max: 588.9
Current: 210.4
-1971.5
588.9
Revenue Growth (%) 21.3
CELG's Revenue Growth (%) is ranked higher than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. CELG: 21.3 )
CELG' s 10-Year Revenue Growth (%) Range
Min: 19.7   Max: 36.3
Current: 21.3
19.7
36.3
EBITDA Growth (%) 22.2
CELG's EBITDA Growth (%) is ranked lower than
82% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. CELG: 22.2 )
CELG' s 10-Year EBITDA Growth (%) Range
Min: 22.2   Max: 122.5
Current: 22.2
22.2
122.5
EPS Growth (%) 18.7
CELG's EPS Growth (%) is ranked lower than
79% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. CELG: 18.7 )
CELG' s 10-Year EPS Growth (%) Range
Min: 18.7   Max: 74.3
Current: 18.7
18.7
74.3
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

CELG Guru Trades in Q2 2012

Joel Greenblatt 22,954 sh (New)
Chuck Royce 4,000 sh (New)
Steven Cohen 623,615 sh (+2330.77%)
Ken Fisher 5,231,453 sh (+1469.11%)
Paul Tudor Jones 18,700 sh (+64.04%)
Jeremy Grantham 147,000 sh (+42.44%)
Jim Simons 1,210,469 sh (+36.55%)
Pioneer Investments 966,991 sh (+13.02%)
Ray Dalio 144,979 sh (+10.27%)
Louis Moore Bacon Sold Out
Mario Gabelli 5,600 sh (-11.11%)
» More
Q3 2012

CELG Guru Trades in Q3 2012

Ronald Muhlenkamp 183,415 sh (New)
John Hussman 500,000 sh (New)
Louis Moore Bacon 35,000 sh (New)
Pioneer Investments 1,289,830 sh (+33.39%)
Ray Dalio 178,381 sh (+23.04%)
Chuck Royce 4,900 sh (+22.5%)
Jeremy Grantham 154,700 sh (+5.24%)
Mario Gabelli 5,200 sh (-7.14%)
Paul Tudor Jones 7,300 sh (-60.96%)
Jim Simons 354,300 sh (-70.73%)
Steven Cohen 147,084 sh (-76.41%)
Joel Greenblatt 3,687 sh (-83.94%)
Ken Fisher 140,931 sh (-97.31%)
» More
Q4 2012

CELG Guru Trades in Q4 2012

Bruce Kovner 52,000 sh (New)
Joel Greenblatt 40,157 sh (+989.15%)
Jim Simons 1,182,469 sh (+233.75%)
Mario Gabelli 8,755 sh (+68.37%)
Steven Cohen 161,155 sh (+9.57%)
Pioneer Investments 1,412,774 sh (+9.53%)
Chuck Royce 4,900 sh (unchged)
Louis Moore Bacon Sold Out
Ronald Muhlenkamp 181,390 sh (-1.1%)
Paul Tudor Jones 6,600 sh (-9.59%)
John Hussman 400,000 sh (-20%)
Ray Dalio 84,881 sh (-52.42%)
Ken Fisher 13,837 sh (-90.18%)
» More
Q1 2013

CELG Guru Trades in Q1 2013

Ken Heebner 280,000 sh (New)
Andreas Halvorsen 425,900 sh (New)
RS Investment Management 53,290 sh (New)
Louis Moore Bacon 150,000 sh (New)
Jim Simons 2,470,669 sh (+108.94%)
Pioneer Investments 1,498,403 sh (+6.06%)
Ronald Muhlenkamp 183,000 sh (+0.89%)
Ray Dalio Sold Out
Mario Gabelli 8,115 sh (-7.31%)
Chuck Royce 2,700 sh (-44.9%)
Bruce Kovner 28,000 sh (-46.15%)
Ken Fisher 7,420 sh (-46.38%)
Paul Tudor Jones 3,300 sh (-50%)
Steven Cohen 63,143 sh (-60.82%)
John Hussman 59,000 sh (-85.25%)
Joel Greenblatt 2,330 sh (-94.2%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Reduce -85.25%0.71%$78.47 - $115.91 $ 123.4422%59000
Joel Greenblatt 2013-03-31 Reduce -94.2%0.17%$78.47 - $115.91 $ 123.4422%2330
Ray Dalio 2013-03-31 Sold Out 0.07%$78.47 - $115.91 $ 123.4422%0
Joel Greenblatt 2012-12-31 Add 989.15%0.16%$71.3 - $82.08 $ 123.4460%40157
Ray Dalio 2012-12-31 Reduce -52.42%0.09%$71.3 - $82.08 $ 123.4460%84881
Mario Gabelli 2012-12-31 Add 68.37%$71.3 - $82.08 $ 123.4460%8755
Ronald Muhlenkamp 2012-09-30 New Buy3%$62.96 - $77.27 $ 123.4476%183415
John Hussman 2012-09-30 New Buy0.92%$62.96 - $77.27 $ 123.4476%500000
Joel Greenblatt 2012-09-30 Reduce -83.94%0.09%$62.96 - $77.27 $ 123.4476%3687
Ray Dalio 2012-09-30 Add 23.04%0.03%$62.96 - $77.27 $ 123.4476%178381
Joel Greenblatt 2012-06-30 New Buy0.11%$59.35 - $80.02 $ 123.4474%22954
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 37.50
CELG's P/E(ttm) is ranked higher than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 20.85 vs. CELG: 37.50 )
CELG' s 10-Year P/E(ttm) Range
Min: 17.91   Max: 603.13
Current: 37.5
17.91
603.13
P/B 9.08
CELG's P/B is ranked lower than
67% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CELG: 9.08 )
CELG' s 10-Year P/B Range
Min: 3.09   Max: 27.45
Current: 9.08
3.09
27.45
P/S 9.46
CELG's P/S is ranked lower than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. CELG: 9.46 )
CELG' s 10-Year P/S Range
Min: 5.37   Max: 93.75
Current: 9.46
5.37
93.75
PFCF 28.18
CELG's PFCF is ranked higher than
72% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 24.02 vs. CELG: 28.18 )
CELG' s 10-Year PFCF Range
Min: 14.78   Max: 3699
Current: 28.18
14.78
3699
EV-to-EBIT 29.58
CELG's EV-to-EBIT is ranked higher than
66% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. CELG: 29.58 )
CELG' s 10-Year EV-to-EBIT Range
Min: 15.1   Max: 802.4
Current: 29.58
15.1
802.4
Shiller P/E 100.86
CELG's Shiller P/E is ranked higher than
74% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CELG: 100.86 )
CELG' s 10-Year Shiller P/E Range
Min: 71.5   Max: 4825
Current: 100.86
71.5
4825

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 61.1
CELG's Price/Net Current Asset Value is ranked higher than
75% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. CELG: 61.1 )
CELG' s 10-Year Price/Net Current Asset Value Range
Min: 39.1   Max: 213.1
Current: 61.1
39.1
213.1
Price/Tangible Book 93.8
CELG's Price/Tangible Book is ranked higher than
98% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. CELG: 93.8 )
CELG' s 10-Year Price/Tangible Book Range
Min: 6.1   Max: 62.8
Current: 93.8
6.1
62.8
Price/DCF (Projected) 2.7
CELG's Price/DCF (Projected) is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. CELG: 2.7 )
CELG' s 10-Year Price/DCF (Projected) Range
Min: 1.8   Max: 53.4
Current: 2.7
1.8
53.4
Price/Median PS Value 0.6
CELG's Price/Median PS Value is ranked higher than
56% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. CELG: 0.6 )
CELG' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.9
Current: 0.6
0.4
1.9
Price/Peter Lynch Fair Value 1.3
CELG's Price/Peter Lynch Fair Value is ranked higher than
93% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. CELG: 1.3 )
CELG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.9   Max: 11
Current: 1.3
0.9
11
Price/Graham Number 12.1
CELG's Price/Graham Number is ranked higher than
98% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. CELG: 12.1 )
CELG' s 10-Year Price/Graham Number Range
Min: 3.3   Max: 13.9
Current: 12.1
3.3
13.9
Earnings Yield (Greenblatt) 3.40
CELG's Earnings Yield (Greenblatt) is ranked higher than
76% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. CELG: 3.40 )
CELG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 6.6
Current: 3.4
0.1
6.6
Forward Rate of Return (Yacktman) 1.42
CELG's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. CELG: 1.42 )
CELG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.8   Max: 2.6
Current: 1.42
-0.8
2.6

Business Description

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. In 1986, it was spun off from Celanese Corporation and, in July 1987, completed an initial public offering. Its initial operations focused on the research and development of chemical and biotreatment processes for the chemical and pharmaceutical industries.The company is dedicated to research and development designed to bring new therapies to market and is involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmunity and placental cell, including stem and progenitor cell, research. The drug and cell therapies Celgene develops are designed to treat life-threatening diseases or chronic debilitating conditions where patients are poorly served by current therapies. In October 2010, it acquired Abraxis Bioscience Inc., or Abraxis, a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients treatments for cancer and other critical illnesses. The acquisition of Abraxis accelerates its strategy to become a global leader in oncology and added ABRAXANE, which is based on Abraxis' proprietary tumor-targeting platform known as nab technology, to its portfolio of cancer products. n January 2010, it acquired Gloucester Pharmaceuticals, Inc., or Gloucester, a privately held pharmaceutical company which developed new therapies that address unmet medical needs in the treatment of hematological cancers, including cutaneous T-cell lymphoma, or CTCL, peripheral T-cell lymphoma, or PTCL, and other hematological malignancies. Gloucester added ISTODAX to its product portfolio and advanced its leadership position in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers. Celgene is investing in a range of innovative therapeutic programs that are investigating ways to treat and manage chronic diseases by targeting the disease source through multiple mechanisms of action. Celgene's commercial stage products include REVLIMID, THALOMID, VIDAZA, ALKERAN and FOCALIN. FOCALIN is sold exclusively to Novartis Pharma AG, or Novartis. Celgene also derives revenues from a licensing agreement with Novartis, which entitles the firm to royalties on FOCALIN XR and the entire RITALIN family of drugs, and sales of bio-therapeutic products and services through its Cellular Therapeutics subsidiary. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in ongoing research and development a
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CMXHY
Traded in other countries:CG3.Germany
» More Articles for CELG

Headlines

Articles On GuruFocus.com
My Best Healthcare Stock Picks For 2013 | Last Year’s Picks Gained 31.55% Dec 04 2012 
Bearish John Hussman Buys 3M, CVS, Western Digital, Sells Humana, Biogen Idec, Broadcom Nov 07 2012 
Growth Stocks: There Is a Lot of Value in this Market Part 2 Sep 27 2012 
Maybe Diversification Is Not All It's Cracked Up to Be Apr 19 2012 
52-Week High Companies: CVS, TSM, PM, ROST, CELG Feb 27 2012 
52-Week High Companies: CELG, MON, ECL, SBUX, NWSA Jan 16 2012 
Weekly Top Insider Buys: AMGN, AEP, ISRG, MMC, CELG Dec 26 2011 
Weekly Top Insider Buys: CELG, VRX, ECL, AVT, NRGY Dec 12 2011 
Weekly CEO Buys Highlight: CTAS, HLX, GGP, CNL, CELG Aug 14 2011 
Weekly Top Insider Buys: PFE, MS, CELG, CHK Aug 08 2011 

More From Our Partners
Gilead's Sofosbuvir under European Review - Analyst Blog May 22 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial